France — Bharat WorldMeds

India ships $328M in pharmaceutical products to France each year, making it the #4 export destination. Both countries track this trade: Eurostat import data confirms the scale. The vast majority are finished medicines — drug formulations ready for dispensing.

Dual-source profile. Both series show finished pharmaceutical products aligned to calendar year (Jan–Dec). Eurostat records what France imports from India. DGCIS records what India exports to France. Category and product detail from DGCIS.

$328M

Scale

France's patients receive $328M in Indian pharmaceutical products annually — almost entirely finished medicines ready for dispensing.

80%

Medicine

Overwhelmingly finished medicines — drug formulations account for 80% of shipments.

4.8×

Trajectory

Rapid expansion: France's imports of Indian pharmaceutical products have grown 4.8× over the past decade, from $68.0M to $328M.

Context

India's #4 pharmaceutical export destination — among the top five globally.

✦

Impact

Indian pharmaceutical companies have both exported to and invested directly in France — building trade and operational presence.

$779M

Ranking Basis

India's official export data (DGCIS, FY 2025–26) records $779M in pharmaceutical products to France — the figure behind the #4 ranking.

Additional pharmaceutical categories from DGCIS — APIs, surgical, herbal, and more

Medicines $623M (79.9%) Medicine Ingredients $116M (14.9%) Traditional & Herbal $24.5M (3.1%) Surgical & Hospital Supplies $13.2M (1.7%) Vaccines $2.8M (0.4%)

Active Pharmaceutical Ingredients DGCIS India-side

India also supplied $120M in active pharmaceutical ingredients and bulk drugs to France in 2025 (India-reported, DGCIS).

Total RBI-approved ODI commitments by Indian pharmaceutical companies into France: $581M across 7 filings (2013-2025).

The relationship flows both ways. French pharmaceutical companies are among the largest investors in India's health ecosystem — operating manufacturing plants, R&D centres, and clinical trial networks across the country.

Sanofi

$44B global revenue

82,878 employees

Dupixent (Immunology) · Beyfortus (Vaccines) · Lantus (Diabetes)